newsfilter
← Latest News
Business Wire·

Bristol Myers Squibb Announces Positive Topline Results from the Interim Analysis of Phase 3 ACTION-1 for RYZ101, RayzeBio’s Radiopharmaceutical Therapy, in Patients with GEP-NETs

The study met the primary endpoint with a statistically significant and clinically meaningful improvement in progression free survival (PFS) Bristol Myers Squibb (NYSE:BMY) today announced positive topline results